These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9154478)

  • 1. Vancomycin-resistant enterococci in stool specimens submitted for Clostridium difficile cytotoxin assay.
    Rafferty ME; McCormick MI; Bopp LH; Baltch AL; George M; Smith RP; Rheal C; Ritz W; Schoonmaker D
    Infect Control Hosp Epidemiol; 1997 May; 18(5):342-4. PubMed ID: 9154478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of vancomycin-resistant enterococci (VRE) in stool specimens submitted for Clostridium difficile toxin testing.
    Özsoy S; İlki A
    Braz J Microbiol; 2017; 48(3):489-492. PubMed ID: 28389190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for vancomycin-resistant enterococci using stools sent for Clostridium difficile cytotoxin assay is effective: results of a survey of 300 Patients in a large Singapore Teaching Hospital.
    Tay JK; Bodle EE; Fisher DA; Lin RV; Kumarasinghe G; Tambyah PA
    Ann Acad Med Singap; 2007 Nov; 36(11):926-9. PubMed ID: 18071603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory-based surveillance for vancomycin-resistant enterococci: utility of screening stool specimens submitted for Clostridium difficile toxin assay.
    Leber AL; Hindler JF; Kato EO; Bruckner DA; Pegues DA
    Infect Control Hosp Epidemiol; 2001 Mar; 22(3):160-4. PubMed ID: 11310695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yield of vancomycin-resistant enterococci and multidrug-resistant Enterobacteriaceae from stools submitted for Clostridium difficile testing compared to results from a focused surveillance program.
    Hacek DM; Bednarz P; Noskin GA; Zembower T; Peterson LR
    J Clin Microbiol; 2001 Mar; 39(3):1152-4. PubMed ID: 11230446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study.
    Lam S; Singer C; Tucci V; Morthland VH; Pfaller MA; Isenberg HD
    Am J Infect Control; 1995 Jun; 23(3):170-80. PubMed ID: 7677262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of the esp gene in Enterococcus faecium derived from oropharyngeal microbiota of haematology patients.
    Jovanović M; Tošić T; Jovanović S; Stošović R; Stevanović G; Velebit B; Zervos MJ
    Arch Oral Biol; 2018 Apr; 88():54-59. PubMed ID: 29407752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epidemiological search for vancomycin-resistant enterococci in mainland of the Ryukyus].
    Kisanuki K; Higa M; Nakasone I; Shiohira CM; Yamane N
    Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi; 2008; 19(1-2):1-6. PubMed ID: 19583456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clostridium difficile infection is a risk factor for bacteremia due to vancomycin-resistant enterococci (VRE) in VRE-colonized patients with acute leukemia.
    Roghmann MC; McCarter RJ; Brewrink J; Cross AS; Morris JG
    Clin Infect Dis; 1997 Nov; 25(5):1056-9. PubMed ID: 9402356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin-resistant enterococci in rooks (Corvus frugilegus) wintering throughout Europe.
    Oravcova V; Ghosh A; Zurek L; Bardon J; Guenther S; Cizek A; Literak I
    Environ Microbiol; 2013 Feb; 15(2):548-56. PubMed ID: 23116146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three surveillance strategies for vancomycin-resistant enterococci in hospitalized patients: detection of colonization efficiency and a cost-effectiveness model.
    Lee TA; Hacek DM; Stroupe KT; Collins SM; Peterson LR
    Infect Control Hosp Epidemiol; 2005 Jan; 26(1):39-46. PubMed ID: 15693407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.
    Nerandzic MM; Mullane K; Miller MA; Babakhani F; Donskey CJ
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S121-6. PubMed ID: 22752860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance for antimicrobial resistance in enterococci.
    Taylor SL; Pottumarthy S; Wong CG; Bremner DA; Morris AJ
    N Z Med J; 1997 Jul; 110(1047):251-3. PubMed ID: 9251710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS).
    Zhanel GG; Laing NM; Nichol KA; Palatnick LP; Noreddin A; Hisanaga T; Johnson JL; Hoban DJ;
    J Antimicrob Chemother; 2003 Sep; 52(3):382-8. PubMed ID: 12888592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vancomycin resistant enterococcal (VRE) colonization among patients treated in intensive care units at the National Hospital of Sri Lanka, and determination of genotype/s responsible for resistance.
    Kannangara C; Chandrasiri P; Corea EM
    Ceylon Med J; 2018 Dec; 63(4):154-158. PubMed ID: 30669209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications for vancomycin-resistant Enterococcus colonization associated with Clostridium difficile infections.
    Fujitani S; George WL; Morgan MA; Nichols S; Murthy AR
    Am J Infect Control; 2011 Apr; 39(3):188-93. PubMed ID: 21458682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colonization with vancomycin-resistant Enterococcus faecium: comparison of a long-term-care unit with an acute-care hospital.
    Bonilla HF; Zervos MA; Lyons MJ; Bradley SF; Hedderwick SA; Ramsey MA; Paul LK; Kauffman CA
    Infect Control Hosp Epidemiol; 1997 May; 18(5):333-9. PubMed ID: 9154476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection.
    Miller M; Bernard L; Thompson M; Grima D; Pepin J
    Infect Control Hosp Epidemiol; 2010 Jul; 31(7):710-5. PubMed ID: 20518636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance for vancomycin-resistant enterococci: type, rates, costs, and implications.
    Shadel BN; Puzniak LA; Gillespie KN; Lawrence SJ; Kollef M; Mundy LM
    Infect Control Hosp Epidemiol; 2006 Oct; 27(10):1068-75. PubMed ID: 17006814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the novel artus C. difficile QS-RGQ, VanR QS-RGQ and MRSA/SA QS-RGQ assays for the laboratory diagnosis of Clostridium difficile infection (CDI), and for vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) screening.
    Morris KA; Macfarlane-Smith LR; Wilcox MH
    Eur J Clin Microbiol Infect Dis; 2017 May; 36(5):823-829. PubMed ID: 27987047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.